# A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients

> **NCT02661100** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Case Comprehensive Cancer Center**

## Conditions studied

- Non Small Cell Lung Cancer
- Advanced Triple Negative Breast Cancer
- Small Cell Lung Cancer
- Urothelial Cancer
- Mesothelioma
- Malignant Melanoma

## Interventions

- **DRUG:** Pembrolizumab
- **BIOLOGICAL:** CDX-1401
- **BIOLOGICAL:** Poly-ICLC

## Key facts

- **NCT ID:** NCT02661100
- **Lead sponsor:** Case Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-01
- **Primary completion:** 2018-07
- **Final completion:** 2018-07
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Drug unavailable
- **Last updated:** 2016-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02661100

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02661100, "A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02661100. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*